Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verdiperstat - Biohaven Pharmaceutical Holding Company

Drug Profile

Verdiperstat - Biohaven Pharmaceutical Holding Company

Alternative Names: AZD 3241; BHV-3241

Latest Information Update: 20 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biohaven Pharmaceutical Holding Company
  • Class Antiparkinsonians; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple system atrophy
  • Discontinued Parkinson's disease

Most Recent Events

  • 18 Sep 2019 Massachusetts General Hospital and Biohaven Pharmaceuticals plans the HEALEY ALS Platform Trial of verdiperstat for Amyotrophic Lateral Sclerosis
  • 23 Jul 2019 Phase-III clinical trials in Multiple system atrophy in USA (PO) (NCT03952806)
  • 19 Feb 2019 Verdiperstat - Biohaven Pharmaceutical Holding Company receives Orphan Drug status for Multiple system atrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top